Provided by Tiger Trade Technology Pte. Ltd.

Pyxis Oncology, Inc.

1.36
-0.0600-4.23%
Post-market: 1.360.00000.00%16:28 EDT
Volume:550.25K
Turnover:765.23K
Market Cap:84.68M
PE:-0.86
High:1.47
Open:1.44
Low:1.35
Close:1.42
52wk High:5.55
52wk Low:0.8332
Shares:62.26M
Float Shares:41.16M
Volume Ratio:1.50
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5736
EPS(LYR):-1.3231
ROE:-91.43%
ROA:-41.14%
PB:1.59
PE(LYR):-1.03

Loading ...

RBC Cuts Price Target on Pyxis Oncology to $5 From $8, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Dec 19, 2025

Pyxis Oncology, Inc. : H.c. Wainwright Raises Target Price to $7 From $5

THOMSON REUTERS
·
Dec 19, 2025

Pyxis Oncology Slips on Data Suggesting High Incidence of Adverse Effects in Cancer-Drug Trials

Dow Jones
·
Dec 19, 2025

Investors Await Key Inflation, Employment Data as US Futures Rise Thursday Pre-Bell

MT Newswires Live
·
Dec 18, 2025

Pyxis Oncology Reports Positive Preliminary Phase 1 Results for MICVO in Head and Neck Cancer

Reuters
·
Dec 18, 2025

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (Micvo) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

THOMSON REUTERS
·
Dec 18, 2025

Pyxis Oncology Inc: Micvo Was Generally Well Tolerated, With No Grade 4 ADC Payload Treatment-Related Adverse Events of Interest Observed

THOMSON REUTERS
·
Dec 18, 2025

Pyxis Oncology Inc: Micvo Well Tolerated With No Grade 5 Events

THOMSON REUTERS
·
Dec 18, 2025

Pyxis Oncology Files $350 Million Mixed Shelf

MT Newswires Live
·
Nov 26, 2025

Pyxis Oncology Inc Files for Mixed Shelf of up to $350 Mln – SEC Filing

THOMSON REUTERS
·
Nov 26, 2025

Pyxis Oncology Inc - Files for $150 Mln Stock Sale Agreement With Leerink Partners - SEC Filing

THOMSON REUTERS
·
Nov 26, 2025

Pyxis Oncology Inc : Leerink Partners Raises Target Price to $9 From $7

THOMSON REUTERS
·
Nov 25, 2025

Pyxis Oncology Is Maintained at Overweight by Stephens & Co.

Dow Jones
·
Nov 24, 2025

Stephens Reaffirms Their Buy Rating on Pyxis Oncology (PYXS)

TIPRANKS
·
Nov 24, 2025

Pyxis Oncology price target raised to $8 from $5 at Stephens

TIPRANKS
·
Nov 24, 2025

Pyxis Oncology Q3 Net Income USD -22.003 Million

Reuters
·
Nov 20, 2025

Pyxis Oncology Reports Increased Losses Amid Development Focus

TIPRANKS
·
Nov 18, 2025

Promising Efficacy of Pyxis Oncology’s MICVO in HNSCC Justifies Buy Rating Despite Financial Constraints

TIPRANKS
·
Nov 15, 2025

Stifel Nicolaus Remains a Buy on Pyxis Oncology (PYXS)

TIPRANKS
·
Nov 13, 2025

RBC Capital Reaffirms Their Buy Rating on Pyxis Oncology (PYXS)

TIPRANKS
·
Nov 05, 2025